"This pilot study reveals significant lipid abnormalities which require further larger more detailed lipid studies to assess the true burden of lipid abnormalities in Ireland. Cascade screening and genetic testing of relatives of those with severe lipid abnormalities should be considered."

This cross-sectional study confirms that MyPlate guidelines and physical activity are vital for managing metabolic syndrome parameters in college students, specifically regarding blood pressure and HDL-C levels. The findings reveal that metabolic risk factors are gender-specific, with exercise and protein/dairy intake being more influential for males, while vegetable and empty calorie consumption are the primary determinants for females. Consequently, while the MyPlate framework is highly effective, these results emphasize the importance of tailoring dietary and lifestyle interventions to gender-specific needs to optimize health outcomes in young adults.

"Continued efforts to treat and prevent elevated weight are urgently needed for minority preschoolers. Attention to CVD screening may be an important target in school, community, and healthcare arenas for minority populations regardless of weight status."

"In obese children, higher cardiovascular fitness appears to reduce the chance of decreased liver function."

"Obese-fit children with abnormal ALT values have a significant reduction in the likelihood to be classified as having MS, even after adjustments for gender, maturation and BMI, Thus, CRF might be an important factor for tackling fatty liver among obese."

"Exertions to increase and maintain walking to school may be particularly relevant as it is likely to have a positive impact on children's health and eventually decrease metabolic and cardiovascular diseases."

"This trial is the first with objective measurement and a comparison group to demonstrate that the introduction of a sit-stand workstation can substantially reduce office workers' sitting time both at the workplace and overall throughout the week."

"There was a minimum mismatch irrespective of the type of risk calculator used. POCT measurements are adequate for the National Health Service Health Check."

"Despite their young age and participation in an elite-level athletic program, many collegiate-level football linemen had features of metabolic syndrome. Although our study focused on a single team, we suspect these trends may be consistent across the country."

"Greater trunk fat mass was associated with higher IR of Australian women of European descent, whereas smaller leg fat mass was associated with higher IR of women of Chinese descent."

"Both screening devices [Cholestech LDX (Cholestech Corporation, Hayward, California) and CardioChek Plus (Polymer Technology Systems Inc, Indianapolis, Indiana)] operated within industry accuracy standards."

The Afinion AS100 provides a reliable, multi-analyte platform for community-based screening, showing strong agreement with laboratory standards and established POCT devices. Despite minor statistical biases, the results are clinically comparable and support accurate cardiovascular risk calculations (QRISK2). Ultimately, this technology enables a "one-stop shop" approach, delivering rapid and dependable results that streamline disease prevention and patient care.

"The optimal approach to capillary lipid screening may be to use [Cholestech LDX and CardioChek] non-HDL cholesterol; as it exhibited little bias relative to CDC reference methods in both fasting and postprandial samples, facilitating lipid screening in non-fasting adults."

"POCT has clear advantages for delivering NHS Health Checks over the laboratory-based approach although device performance [Cholestech LDX and CardioChek PA] does differ. Users should also be aware of the potential clinical governance and interference issues associated with these devices."

"Identification of subjects at risk of CVD depends on the cardiovascular risk algorithm and also on the performance of the POCT device [Cholestech LDX and CardioChek PA]."

"Analytical performance of the POC analysers were generally similar, however, there were significant differences in operational characteristics and ease of use. Bias for the different analytes when compared to the laboratory analyser ranged from -27% to 14%. Calculated total errors for all analytes except for HDL cholesterol were within total allowable error recommendations. The two instruments (Roche Reflotron and Cholestech LDX) with the highest overall total points achieved the highest scores for ease of use. This pilot study has led to the development of a scoring system for the evaluation of POC instruments."

"The methods established for the implementation and delivery of training and competency assessment for the PoCT [Siemens DCA 2000 (Siemens HealthCare Diagnostics, Melbourne, VIC, Australia) for HbA1c and urine ACR; Point of Care Diagnostics Cholestech LDX analyser (Point of Care Diagnostics; Sydney, NSW, Australia) for lipids; and the Roche CoaguChek S (Roche Diagnostics; Sydney, NSW, Australia) for INR.] in General Practice Trial were appropriate and effective. Results of the evaluation showed rural and remote practices have a greater need for training and support compared to their urban counterparts and may require more flexible training options to cater for much higher rates of staff turnover."

"The Cholestech LDX analyzer demonstrated better reproducibility than the CardioChek PA analyzer when compared with laboratory gold standard analysis and allowed more accurate categorization for FRS. Since results obtained from these analyzers have the potential to impact treatment decisions, larger, prospective, comparative studies seem warranted."

This study demonstrates that the Cholestech LDX outperforms the CardioChek PA in terms of precision, correlation, and accuracy. Unlike the CardioChek, which showed significant bias and failed most NCEP total error goals, the Cholestech LDX aligned closely with laboratory standards. Therefore, the Cholestech LDX is a suitable POCT device for primary care cardiovascular risk assessment, while the CardioChek PA requires further refinement.

Both the CardioChek PA and Cholestech LDX showed a significant correlation with laboratory methods and largely met NCEP performance goals. Although both devices under-read lipid levels in the high range, their overall accuracy and speed make them acceptable POC tools for rapid lipid measurement in clinical settings.

"We found that evidence for two of the devices mostly met the requirements of the NCEP standard of evidence for bias and precision and could be recommended to general practitioners to use in the NHS Health Check programme. These were the Cholestech LDX and the Cobas b101 system."

"The results confirm the acceptable analytical performance of POCT pharmacies and specific criticisms in the pre- and post-analytical phases."

"Fingerstick screening is accurate and has good clinical utility to identify persons with abnormal blood lipids and hsCRP at the point of care in a diverse population that is eligible for primary prevention of CVD. These results may not be generalizable to patients at high risk for CVD or who have known hyperlipidemia."

"These results validate the use of the Cholestech LDX analyser for point of care lipid measurements in clinical practice, provided well trained operators are supported by a hospital laboratory delivering quality assurance support."

"Lipid values obtained from portable lipid analyzers may be useful for screening, but they should not be used to make clinical decisions regarding the diagnosis and management of dyslipidemia in individual patients."

"Although the Cholestech L.D.X analyzer did not consistently meet NCEP standards for acceptable total measurement error of TC, HDL, and triglyceride analyses, it seems capable of providing reasonable lipid profile measures in both a screening setting and a clinician office where the goal is correct classification of patients' results."

"Precision and accuracy of lipids evaluation by the Cholestech-LDX are within the guidelines of the National Cholesterol Education Program. Therefore the cholestech-LDX seems to be a reliable alternative to the conventional biochemical routine, allowing population screenings."

The Cholestech LDX analyzer provides accurate and reliable measurements of total cholesterol, HDL, and triglycerides, showing strong correlation with established laboratory methods. Its compact design, ease of use, and rapid results make it an excellent tool for immediate lipid profile testing in primary care and outpatient settings.

"POC instruments provided a reliable alternative to conventional laboratory methods for screening for chronic disease risk factors in locations remote from urban centres."